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Introduction: Prostate embryonal rhabdomyosarcoma (ERMS) is a common tumour in infants
and  children, with a median occurrence age of 5 years, but it is rare in adults. It is character-
ized  by a high degree of malignancy, both local rapid growth with formation of large pelvic
masses, often leading to renal failure due to urethral obstruction, and systemic spread, com-
monly to the lungs, liver and bone. Several therapeutic approaches have been employed in
the  effort to treat prostate ERMS, but all of them have failed to gain a signiﬁcant survival
beneﬁt in adult patients.
Case report: We  report on a case of a stage IV prostate ERMS, approached with combined-
modality treatment, with the administration of 5 courses of doxorubicin, ifosfamide and
2-mercaptoethane sulfonate sodium (mesna), and, subsequent radiotherapy to the prostatic
bed (60 Gy/30 fxs). The patient remained free of progression of disease for about 1 year to
ﬁnally experience a systemic relapse with multiple lung metastases and pleural effusion.
The  patient died for metastatic disease 27 months following the initial diagnosis.
Conclusion: While it remains questionable which therapeutic approach for prostate ERMS
in  adults is the most appropriate, our report demonstrates that a chemo-radiation com-bined  treatment can control the prostate disease, reducing the symptoms and improving
the quality of life of these patients, for the most part destined to die for systemic progression
of  disease.
© 2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
alveolar histiotypes, generally affecting young children and1.  BackgroundRhabdomyosarcoma (RMS) is the most frequent soft tissue
tumour in paediatric patients, accounting for up to 50% of
all soft tissue sarcomas.1 In adults RMS  is very rare2 and
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clinical experience is limited to case reports. Three histological
subtypes have been identiﬁed: embryonal with botryoid andnta Maria Nuova, viale Risorgimento 9, 42123 Reggio Emilia, Italy.
adolescents,3 and the pleomorphic histiotype that is usually
encountered in adult patients.2 This neoplasm has a mes-
enchymal origin, involves skeletal muscle, and therefore can
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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e localized in almost any site. In paediatric patients, it is
ost frequently localized in the cervical-cephalic region and
enito-urinary system; in adults, RMS  involving the thorax
nd extremities accounts for 2–5% of all soft tissue sarcomas.4
he primary prostate embryonal rhabdomyosarcoma (ERMS)
s rare in adults and its clinical manifestations, natural his-
ory, prognosis and treatment options can be found only in
necdotal descriptions. It is usually characterized by extensive
oco-regional spread, with symptoms of urinary obstruction
due to bladder outlet obstacle), and a tendency to metasta-
ize by blood stream and regional lymphatics and to give early
ung and bone involvement.
Several therapeutic approaches have been employed in the
anagement of ERMS of the prostate, such as radical surgery,
adiotherapy and chemotherapy. This combined approach has
igniﬁcantly improved the outcome, in terms of survival and
uality of life in children, while in adults the prognosis has
een poor.
We  herein present a case of 27-year-old male affected by
tage IV ERMS of the prostate treated with a combined chemo-
adiotherapy approach, resulting in a disease-free survival of
 years and a good quality of life, with a complete remission
f the urinary symptoms. Moreover, we  provide a systematic
verview of all reported cases available within the medical
iterature.
.  Case  report
n October 2007, a 27-year-old male was referred to a prac-
itioner because of dysuria and fever. Over the past three
eeks, he had noticed occasional difﬁculty and increased fre-
uency of micturition, as well as anorexia and weight loss. The
atient started treatment with antibiotic but, after 2 days, he
as hospitalized with clinical signs and symptoms of acutef prostate gland and multiple nodules in both lungs.
urinary retention. On catheterisation, 800 ml  of urine could be
rescued. Physical examination was unremarkable, except for
digital rectal examination which revealed an uneven swollen
and enlarged prostate gland of stony-hard consistency with
an irregular capsule proﬁle.
His family history was irrelevant. The patient had been
healthy until the time of our observation and denied venereal
infection, allergy and the use of alcohol and tobacco.
A complete diagnostic work-up was planned. Laboratory
data were unremarkable. Blood chemistry showed normal
levels of prostate-speciﬁc antigen (PSA). Urine examinations
showed a heavy trace of albumin and many  red blood cells.
An abdominal computed tomography (CT) scan was then
performed, disclosing a large mass (62 mm × 50 mm × 61 mm)
of prostatic origin ﬁlling the pelvis, with disruption of the
prostate anatomy and suspected inﬁltration of bladder base
and rectal wall (Fig. 1). No enlarged lymph nodes were detected
at any abdominal site. Chest CT images showed multiple (>20)
bilateral nodular densities with maximum diameter of 1 cm,
of clear metastatic nature (Fig. 1). Pelvic magnetic resonance
(MR) study conﬁrmed the CT ﬁndings. The pathological mass
replaced the entire prostate gland, destroyed the seminal vesi-
cles and inﬁltrated the recto-vesical space and rectal wall.
A subsequent FDG-positron emission tomography (PET) scan
was performed and revealed prostate and bilateral lung patho-
logical uptake; no signs of other sites of disease, as reported
in Fig. 2.
A prostate transrectal biopsy was performed and histol-
ogy showed sheets of multinucleated cells in addition to
small round cells. The round cells demonstrated immuno-
histochemical positivity for muscle-speciﬁc markers, such as
myoglobin, actin and desmin and negativity for citocheratine
(AE1/AE3), CD34, S100 protein and PSA. Proliferation index,
evaluated with Ki67/MIB1 antibodies, was high (>30%). This
account was referable to ERMS of the prostate, classiﬁed as
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tate aFig. 2 – CT/PET scan at diagnosis: pros
high-risk, according to the criteria of the Intergroup Rhab-
domyosarcoma Study Group (IRSG).
A surgeon oncologist was consulted, and because of the
local extension to rectal wall the tumour was regarded as
primary unresectable. Thus, also in view of the metastatic dif-
fusion, the patient underwent ﬁrst-line chemotherapy, with
doxorubicin 25 mg/mq/die d 1, 2, 3, ifosfamide 2000 mg/mq/die
in 2 h d 1, 2, 3, 4, 5, and 2-mercaptoethane sulfonate sodium
(mesna) for 5 cycles. After chemotherapy completion, CT and
CT/PET showed a complete remission of pulmonary disease
and partial response of the prostate mass.
Subsequently, the patient underwent a full course of inten-
sity modulated radiation therapy (IMRT) with Tomotherapy
Hi-Art, up to 60 Gy in 30 fractions to the prostate bed. Treat-
ment was well tolerated, without acute toxicity.
After therapy had been completed, the patient was peri-
odically controlled, with a clinical and radiological follow-up.
A CT-scan, performed every 3 months, revealed a major
downsizing of the prostate tumour and persistent complete
remission of the multiple pulmonary nodules. Pelvic CT-scan
images, performed 6 months after RT completion, are shown
in Fig. 3. The patient remained free from progression of dis-
ease for 17 months without urinary symptoms and with a good
quality of life.
Unfortunately, at 17 months following the radiotherapy
completion, he developed symptoms of fatigue, dyspnoea and
pain in the right thorax. CT scan (Fig. 4) revealed multiple lung
metastases with pleural effusion. No response was seen to pal-
liative chemotherapy (Ecteinascidin-743) and the patient died
for metastatic disease (pulmonary failure) 27 months follow-
ing the initial diagnosis.
3.  Discussion
Primary ERMS of the prostate gland is an extremely rare
pathological and clinical entity in adults,5 with fewer than
twelve cases reported in literature.6 The natural history of the
prostate RSM, deduced from the few cases published in lit-
erature, is characterized by a rapid growth, with the typical
formation of large pelvic or abdominal masses, often leading
to renal failure due to bilateral urethral/ureteral obstruc-
tion. The tumour often disseminates widely, mainly to the
lungs, bone, liver, and serosal surfaces and, unlike most othernd bilateral lung pathological uptake.
sarcomas, regional lymph node metastases are common. The
presenting symptoms are often related to urethral obstruc-
tion, with frequency, hesitancy, and dysuria as predominant
symptoms or, less often, with hematuria and acute urinary
retention. In some patients, the compression of the rectum
can cause constipation, rectal bleeding and a sense of rectal
fullness.7
There is no pathognomonic radiological ﬁnding for prostate
ERMS. CT scan and MRI study reveal a large soft tissue mass
with areas of necrosis replacing the whole prostate, but the
radiological differential diagnosis with prostate adenocarci-
noma can be very difﬁcult. The mass may invade periurethral
and perivesical tissue or it may extend into the ischiorec-
tal fossa. Calciﬁcations are rare. MRI can clearly show the
site of origin as the central prostate area, with compres-
sion of a recognizable peripheral portion. The mass can
display a well-deﬁned low signal intensity pseudocapsule in
T2 weighted images and a heterogeneous enhancement in
post-Gadolinium T1 weighted images. The utilization of PET-
CT for ESRM staging in adults is still to be consolidated in the
literature, however, some reports have demonstrated the rel-
evance of this method in the detection of the primary focus in
metastatic disease or obscure metastases.
The diagnosis is usually performed with a transurethral,
transrectal or perineal biopsy. Histopathological evaluation
can reveal variable grade of differentiation along the myoge-
nesis pathway, and strap cells or myotubes may appear. In
well-differentiated ERMS, the recognition of rhabdomyoblasts
directs the pathologist to the correct diagnosis, above all when
the combined light and electron microscopic studies have
been used. In the major part of cases, immunohistochemistry
for skeletal muscle speciﬁc markers, such as antisera against
myoglobin and skeletal muscle actin and myosin, can help
identify the tumour as rhabdomyosarcoma.
In children, the treatment and prognosis of rhabdomyosar-
coma of the urogenital tract have changed dramatically over
the past few decades. Until the 1970s radical prostatec-
tomy was the only therapeutic option. Since then, multiagent
chemotherapy has achieved remarkable cure rates, with the
goal to improve patients’ quality of life.In adults, rhabdomyosarcoma of the prostate is a very
rare malignancy with a poor prognosis secondary to aggres-
siveness of tumour growth, lack of early symptoms and late
presentation. Moreover, 25% of prostate ESRM patients show
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gFig. 3 – Pelvic CT scan 6 months after radiot
istant metastases at the time of diagnosis. The treatment
ption largely depends on the disease stage at the time of
ppearance. A localized prostate disease can be treated with
adical surgery.8,9 Unfortunately, prostate rhabdomyosarcoma
s often caught late in the disease process, and the tumour size
t time of surgical resection is commonly too extensive, as in
ur patient’s case. Patients with non-metastatic large prostate
RMS, which is not initially resectable, can be treated with
eo-adjuvant chemo-radiation therapy.
Conversely, the impact and optimal timing of local ther-
py for metastatic disease is unknown. A recent study showed
hat, for metastatic rhabdomyosarcoma, radiotherapy was the
nly signiﬁcant factor in improved progression free survival
nd overall survival.10 In the 25 patients with metastatic dis-
ase, median progression free survival times in patients with
r without local therapy (surgery and/or radiotherapy) were
3.4 versus 7.0 months (p < 0.001), respectively, and median
verall survival times were 36.1 versus 7.6 months (p < 0.001),
espectively. Then, the local therapy to the primary tumour
ite during the treatment approach may be necessary for
etastatic rhabdomyosarcoma, as the patients who received
ocal therapies showed signiﬁcantly longer survival than those
ho  did not. Obviously, the timing of local therapy should be
ndividually determined depending on patient conditions and
haracteristics.
Lee et al.11 recently reported a retrospective review of 48
atients with urological sarcoma treated with a multidisci-
linary therapy. The results of this study suggest that any type
f local approach (surgery or radiotherapy) can provide the
est chance of survival in patients with or without metastasis.
In a recent review, Ashlock and colleagues reported an
mprovement of the outcome, in terms of survival and qual-
ty of life in children treated with a multimodality therapy.
evertheless, in adults the prognosis remains poor, despite a
ood initial response to chemotherapy, with all patients dyingpy completion: reduction of prostate mass.
of disseminated disease within 16 months from the diagnosis
(mean survival, 8 months).12
To date, there is no consensus policy on the treatment of
prostate rhabdomyosarcoma of the adult, due to the small
number of cases reported in the literature and to enormous
variability of its management.
Ewing et al.13 reported 3 cases of prostate RMS  in young
adults and Culver14 4 cases of ERMS in a series of 76 patients
affected by primary prostate sarcomas. Katzmann et al.15 pub-
lished a paper on 30 cases of prostate malignant sarcoma,
among which there were 3 cases of RMS. Recently, Nabi et al.16
reported two cases of adults prostate ERMS with poor progno-
sis for both. In addition, Esnaola et al.17 reported, in a series of
30 adults with rhabdomyosarcoma, seven patients affected by
prostate rhabdomyosarcoma, four of which were submitted
to radical surgery and three to radio-chemotherapy. In this
report, there were no 5-year survivors among patients with
prostate tumours, whereas the 5-year-survival rates were 42%,
42% and 15% for head and neck, extremity and truncal local-
izations, respectively. Previous series of adults with prostatic
rhabdomyosarcoma have reported similarly poor results, sug-
gesting that the natural history of genitourinary tract tumours
is signiﬁcantly different in these patients in comparison to
children, independently from the therapeutic approach.6,18
It appears evident that no deﬁnitive conclusions can be
drawn up to now regarding the best available treatment option
towards prostate ERMS in adults. Nonetheless, certain fea-
tures might be noteworthy.
In a clinical situation of an organ-conﬁned disease, radical
surgical extirpation should be performed. The extent of the
surgical procedure remains unclear. In contrast, in the case of
locally advanced disease the surgery can lead to severe impair-
ment of function and its therapeutic gain is questionable.
Furthermore, it should be considered that most of the non-
metastatic patients die in a short time for systemic spread of
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Fig. 4 – Total body CT scan at moment of progression disease: appearance of multiple nodules in bilateral lung and large
is cabilateral pleural effusion and diffuse pulmonary lymphangit
disease, even if locally treated. As alternative to surgery, radia-
tion therapy combined with chemotherapy might be useful to
achieve local control with organ functional preservation and
good quality of life. In our experience, RT resulted in an effec-
tive approach in a prostate ERMS adult patient with advanced
disease. The delivered dose of 60 Gy was able to control locally
the disease without toxicity. The chemotherapeutic schema
adopted in our patient (doxorubicin ifosfamide, mesna) was
initially useful, but the most effective drugs to be used have
yet to be established.
More  data and further studies are needed in the future in
order to improve the understanding of biological behaviour ofrcinomatosa.
prostate ERMS in adults and to deﬁne the most appropriate
therapeutic approach, as well as the timing of local therapy in
metastatic disease.
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